Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Recursion Pharmaceuticals, Inc.’s stock price such as:

• Recursion Pharmaceuticals, Inc.’s current stock price and volume
• Why Recursion Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for RXRX from analysts
• RXRX’s stock price momentum as measured by its relative strength

About Recursion Pharmaceuticals, Inc. (RXRX)

Before we jump into Recursion Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Want to learn more about Recursion Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Recursion Pharmaceuticals, Inc..

Recursion Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of February 27, 2026, 4:00 PM, CST, Recursion Pharmaceuticals, Inc.’s stock price was $3.670.

Recursion Pharmaceuticals, Inc. is down 2.65% from its previous closing price of $3.770.

During the last market session, Recursion Pharmaceuticals, Inc.’s stock traded between $3.570 and $3.720. Currently, there are approximately 526.72 million shares outstanding for Recursion Pharmaceuticals, Inc..

Recursion Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Recursion Pharmaceuticals, Inc. Stock Price History

Recursion Pharmaceuticals, Inc.’s (RXRX) price is currently down 12.41% so far this month.

During the month of February, Recursion Pharmaceuticals, Inc.’s stock price has reached a high of $4.290 and a low of $2.980.

Over the last year, Recursion Pharmaceuticals, Inc. has hit prices as high as $7.890 and as low as $2.980. Year to date, Recursion Pharmaceuticals, Inc.’s stock is down 10.27%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Recursion Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 27, 2026, there were 0 analysts who downgraded Recursion Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Recursion Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Recursion Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Recursion Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Recursion Pharmaceuticals, Inc. (RXRX) by visiting AAII Stock Evaluator.

Relative Price Strength of Recursion Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 27, 2026, Recursion Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -18.30%, which translates to a Momentum Score of 11 and is considered to be Very Weak.

Want to learn more about how Recursion Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Recursion Pharmaceuticals, Inc. Stock Price: Bottom Line

As of February 27, 2026, Recursion Pharmaceuticals, Inc.’s stock price is $3.670, which is down 2.65% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Recursion Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.